Livedo reticularis associated with autoimmune hemolytic anemia: prolonged remission induced by peripheral blood stem cell transplantation relapse after 10 years and restoration of hemoglobin levels by rituximab.

Abstract	Autoimmune hemolytic anemia (AIHA) is a disease where patients produce antibodies against erythrocytes directed towards membrane glycoproteins adsorbed onto the erythrocyte surface. Drugs and other associations have been implicated. It is described and discussed a case of livedo reticularis associated with AIHA treated with peripheral blood stem cell transplantation (PBSCT) that went into full remission for 10 years. After that period the patient relapsed and was treated with antibody anti-CD20, rituximab, and is now in full remission. The role of PBSCT and rituximab in the treatment of AIHA will be discussed.
Authors	Eurípedes Ferreira, Andrezza Feitosa, Nelson Hamerschlak, Morton Aaron Scheinberg
Journal	Revista brasileira de reumatologia (Rev Bras Reumatol) 2012 Jan-Feb Vol. 52 Issue 1 Pg. 122-4 ISSN: 1809-4570 [Electronic] Brazil
PMID	22286652 (Publication Type: Case Reports, Journal Article)
Chemical References	Antibodies, Monoclonal, Murine-Derived Immunologic Factors Rituximab
Topics	Aged Anemia, Hemolytic, Autoimmune (complications, drug therapy, surgery) Antibodies, Monoclonal, Murine-Derived (therapeutic use) Female Humans Immunologic Factors (therapeutic use) Livedo Reticularis (complications, drug therapy, surgery) Peripheral Blood Stem Cell Transplantation Recurrence Remission Induction Rituximab Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!